Please login to the form below

Not currently logged in
Email:
Password:

Novocure’s chief commercial officer to step down

Peter Melnyk will leave the oncology specialist on 15 March

Novocure Peter MelnykPeter Melnyk, Novocure's chief commercial officer is set to step down from 15 March this year.

Melnyk joined the oncology specialist in 2011, taking on responsibility for its global marketing and sales efforts.

Previously, he was senior vice president for sales and marketing at OSI Pharmaceuticals, where he led the global commercialisation of Tarceva (erlotinib) from 2003 to 2011.

Prior to this, Melnyk served as executive director of oncology at Pfizer and a director of oncology at Bristol-Myers Squibb.

Asaf Danziger, Novocure's chief executive officer, said: “I want to thank Peter for his more than five years of leadership at Novocure.

“During his tenure, Peter developed our commercial business model, launched the Optune brand and drove eight consecutive quarters of active patient and revenue growth after the presentation of our EF-14 clinical data in Q4 2014.

“Peter leaving our commercial organisation in a strong position to continue its success. I look forward to following Peter's continued accomplishments as he begins the next chapter of his career.”

7th March 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...